| Jason Forgeon, MD | |
|
1501 Hiland Ave, Burley, ID 83318-2688 | |
| (208) 678-4444 | |
| Not Available |
| Full Name | Jason Forgeon |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1501 Hiland Ave, Burley, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952961732 | NPI | - | NPPES |
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
These days people usually don't die from a heart attack. But the damage to heart muscle is irreversible, and most patients eventually succumb to congestive heart failure, the most common cause of death in developed countries.Stem cells now offer hope for achieving what the body can't do: mending broken hearts. Engineers and physicians at the University of Washington have built a scaffold that supports the growth and integration of stem cell-derived cardiac muscle cells. A description of the scaffold, which supports the growth of cardiac cells in the lab and encourages blood vessel growth in living animals, is published this week in the Proceedings of the National Academy of Sciences.
The Greater Boston Business Council honored UMass Medical School's Work Without Limits program with its Outstanding Business Member of the Year Award for Excellence in Community Service at its recent annual awards ceremony.
For many types of cancer, the original tumor itself is usually not deadly. Instead, it's the spread of a tiny subpopulation of cells from the primary tumor to other parts of the body—the process known as metastasis—that all too often kills the patient.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
The team claims that they have cleared a hurdle to the construction of a prosthetic suit that will enable the paralyzed to walk, as well as restore their sense of touch. They are working towards the opening day of the 2014 World Cup soccer tournament in Brazil when they hope to send in a young quadriplegic striding out to playing fields to open the games.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Forgeon, MD Po Box 30180, Salt Lake City, UT 84130-0180 Ph: () - | Jason Forgeon, MD 1501 Hiland Ave, Burley, ID 83318-2688 Ph: (208) 678-4444 |
News Archive
These days people usually don't die from a heart attack. But the damage to heart muscle is irreversible, and most patients eventually succumb to congestive heart failure, the most common cause of death in developed countries.Stem cells now offer hope for achieving what the body can't do: mending broken hearts. Engineers and physicians at the University of Washington have built a scaffold that supports the growth and integration of stem cell-derived cardiac muscle cells. A description of the scaffold, which supports the growth of cardiac cells in the lab and encourages blood vessel growth in living animals, is published this week in the Proceedings of the National Academy of Sciences.
The Greater Boston Business Council honored UMass Medical School's Work Without Limits program with its Outstanding Business Member of the Year Award for Excellence in Community Service at its recent annual awards ceremony.
For many types of cancer, the original tumor itself is usually not deadly. Instead, it's the spread of a tiny subpopulation of cells from the primary tumor to other parts of the body—the process known as metastasis—that all too often kills the patient.
GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.
The team claims that they have cleared a hurdle to the construction of a prosthetic suit that will enable the paralyzed to walk, as well as restore their sense of touch. They are working towards the opening day of the 2014 World Cup soccer tournament in Brazil when they hope to send in a young quadriplegic striding out to playing fields to open the games.
› Verified 5 days ago
Daniel M Henrie, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1501 Hiland Ave, Burley, ID 83318 Phone: 208-678-4444 |